- Home
- BYSI vs GBIO Comparison
BYSI vs GBIO Comparison
Compare BYSI & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BYSI
- GBIO
- Stock Information
- Founded
- BYSI 2010
- GBIO 2016
- Country
- BYSI United States
- GBIO United States
- Employees
- BYSI N/A
- GBIO N/A
- Industry
- BYSI Biotechnology: Pharmaceutical Preparations
- GBIO Biotechnology: Pharmaceutical Preparations
- Sector
- BYSI Health Care
- GBIO Health Care
- Exchange
- BYSI Nasdaq
- GBIO Nasdaq
- Market Cap
- BYSI 69.3M
- GBIO 64.8M
- IPO Year
- BYSI 2017
- GBIO 2020
- Fundamental
- Price
- BYSI $1.72
- GBIO $0.95
- Analyst Decision
- BYSI
- GBIO Strong Buy
- Analyst Count
- BYSI 0
- GBIO 2
- Target Price
- BYSI N/A
- GBIO $6.50
- AVG Volume (30 Days)
- BYSI 21.8K
- GBIO 749.9K
- Earning Date
- BYSI 01-01-0001
- GBIO 03-05-2025
- Dividend Yield
- BYSI N/A
- GBIO N/A
- EPS Growth
- BYSI N/A
- GBIO N/A
- EPS
- BYSI N/A
- GBIO N/A
- Revenue
- BYSI $1,876,000.00
- GBIO $18,582,000.00
- Revenue This Year
- BYSI N/A
- GBIO $212.74
- Revenue Next Year
- BYSI N/A
- GBIO N/A
- P/E Ratio
- BYSI N/A
- GBIO N/A
- Revenue Growth
- BYSI 21.03
- GBIO 514.08
- 52 Week Low
- BYSI $0.82
- GBIO $0.75
- 52 Week High
- BYSI $4.00
- GBIO $4.65
- Technical
- Relative Strength Index (RSI)
- BYSI 52.47
- GBIO 35.95
- Support Level
- BYSI $1.58
- GBIO $0.86
- Resistance Level
- BYSI $1.75
- GBIO $1.01
- Average True Range (ATR)
- BYSI 0.09
- GBIO 0.12
- MACD
- BYSI 0.02
- GBIO 0.01
- Stochastic Oscillator
- BYSI 74.07
- GBIO 25.13
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It has two reportable segments Plinabulin pipeline and the TPD platform.
About GBIO Generation Bio Co.
Generation Bio Co is a genetics medicine company that is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.